Related Experiment Video

Updated: Mar 26, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K

ABCB5-Targeted Chemoresistance Reversal Inhibits Merkel Cell Carcinoma Growth

Sonja Kleffel1, Nayoung Lee1, Cecilia Lezcano2

  • 1Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

The Journal of Investigative Dermatology
|February 2, 2016
PubMed

Insights

Merkel cell carcinoma (MCC) drug resistance is linked to ATP-binding cassette member B5 (ABCB5). Blocking ABCB5 can resensitize MCC tumors to chemotherapy, offering a new therapeutic strategy for this aggressive skin cancer.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer.
  • Chemotherapy resistance significantly limits effective MCC treatment.
  • The mechanisms underlying MCC chemoresistance are not fully understood.

Purpose of the Study:

  • To investigate the role of ATP-binding cassette member B5 (ABCB5) in MCC chemoresistance.
  • To evaluate ABCB5 as a potential therapeutic target for overcoming drug resistance in MCC.
  • To demonstrate the efficacy of ABCB5 blockade in combination with chemotherapy.

Main Methods:

  • Analysis of ABCB5 expression in MCC cell lines and clinical specimens.
  • Assessment of MCC cell survival and tumor growth in vitro and in vivo under chemotherapy treatment.
  • Evaluation of ABCB5 blockade effects on drug sensitivity and tumor progression in MCC xenograft models.

Main Results:

  • ABCB5 expression is significantly elevated in MCC compared to normal skin and is further upregulated in chemoresistant MCC cells.
  • ABCB5-expressing MCC cells exhibit preferential survival during carboplatin and etoposide treatment.
  • ABCB5 blockade reverses drug resistance and inhibits MCC tumor growth in preclinical models.
  • Increased ABCB5 positivity in patients post-chemotherapy suggests clinical relevance.

Conclusions:

  • ABCB5 is a key mechanism conferring chemoresistance in Merkel cell carcinoma.
  • Targeting ABCB5 represents a promising strategy to enhance chemotherapy efficacy and improve outcomes for MCC patients.
  • ABCB5 blockade can overcome established drug resistance in MCC, offering a novel therapeutic avenue.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K